Imperial Collage Healthcare

FISH analysis for B Lymphobasticleukaemia/lymphoma


Test Background
FISH involves the application of fluorescent DNA probes specific to genes or genetic regions of interest that highlight abnormalities involving these regions.


Clinical Indications

  • Conventional cytogenetic analysis is carried out routinely on diagnostic ALL samples, in addition to a panel of FISH probes for the rapid investigation of known prognostic markers. Further FISH may also be used at the discretion of the laboratory.

  • In cases of ALL, FISH is useful in the following scenarios:

  • •           Rapid investigation of prognostic markers at diagnosis that are likely to impact on patient management (ie BCR-ABL1 in adults; and BCR-ABL1 and ETV6-RUNX1 in children)

  • •           Identifying aberrations that are known to be cryptic at the level of conventional cytogenetics (eg some rearrangements of MLL)

  • •           In cases where a sample has failed to produce metaphases, or in which the disease cells are suspected of having failed to divide.

  • •           To monitor residual disease in a patient previously found to carry a FISH-detectable aberration.

  • In addition to the mandatory diagnostic panel, further FISH probes may be applied to diagnostic samples, including – but not limited to – those in the below list. This will be at the discretion of the laboratory and according to the findings of conventional cytogenetic analysis or other investigations.

  • CDKN2A                        9q21

  • MLL                             11q23

  • TP53                           7p13

  • IGH and related partner genes

  • RUNX1                         21q22

  • Chromosome enumeration probes

  • Where possible, follow-up samples are monitored by FISH only, unless frank relapse and/or disease progression are suspected, in which case conventional karyotyping will be performed in the first instance.


Reference Range

N/A


Sample Required
See notes section


Sample Volume
Samples would not be rejected on the basis of small volume, however, 5 mL is ideal.


Turnaround Time
See notes section


Notes
Sample required:

Bone marrow in cytogenetic transport medium (preferred) or lithium heparin is usually the sample of choice, but peripheral blood in lithium heparin may be suitable if there are circulating blasts and/or a high white blood cell count. EDTA samples are only suitable in cases requiring FISH only (ie follow-up samples from patients with FISH-detectable abnormalities, or blood samples taken at diagnosis for exclusion of a specific gene fusion when a bone marrow sample will shortly follow). If in doubt please use lithium heparin. Samples which are non-sterile, clotted or collected in sodium citrate, fixative or saline are not suitable. To ensure appropriate analysis and interpretation it is important to provide clear and concise clinical information.


Turnaround times:


Rapid FISH tests (exclusion of specific genetic subtypes at diagnosis): 95% should be reported within 3 working days as a “preliminary result”. The remaining conventional cytogenetic analysis will be included in a final report, including any additional FISH, within 10 calendar days if rapid FISH was negative, or < 21 calendar days if rapid FISH was positive.


•           Post treatment follow-up samples are treated as routine; 95% should be reported within 21 calendar days

Filter by A-Z

Select a test from the left to view more details.